The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality

被引:13
|
作者
Zhou, Yanling [1 ,2 ]
Wang, Chengyu [1 ,2 ]
Lan, Xiaofeng [1 ,2 ]
Zheng, Wei [1 ,2 ]
Li, Hanqiu [1 ,2 ]
Chao, Ziyuan [1 ,2 ]
Wu, Kai [1 ,2 ,3 ]
McIntyre, Roger S. [4 ,5 ,6 ,7 ,8 ,9 ]
Ning, Yuping [1 ,2 ,10 ]
机构
[1] Guangzhou Med Univ, Guangzhou Huiai Hosp, Affiliated Brain Hosp, Guangzhou, Peoples R China
[2] Guangdong Engn Technol Res Ctr Translat Med Menta, Guangzhou, Peoples R China
[3] South China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou, Peoples R China
[4] Canadian Rapid Treatment Ctr Excellence, Mississauga, ON, Canada
[5] Univ Hlth Network, Poul Hansen Depress Ctr, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[7] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
[8] Brain & Cognit Discovery Fdn, Toronto, ON, Canada
[9] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[10] Southern Med Univ, Sch Clin Med 1, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Cognition; Ketamine; Depression; Treatment resistance; Suicidality; DOUBLE-BLIND; NEUROCOGNITIVE PERFORMANCE; FUNCTIONAL OUTCOMES; ANTIDEPRESSANT; EFFICACY; ASSOCIATION; ESKETAMINE; IMPAIRMENT;
D O I
10.1016/j.jpsychires.2021.10.037
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Ketamine has rapid and robust antidepressant effects in depression, while its effects on cognitive measures are less clearly understood. This aim of the study herein is to determine whether ketamine has direct pro-cognitive effects in real-world treatment depression and/or suicidality. Methods: Subjects with unipolar (n = 84) and bipolar (n = 27) depression suffering treatment resistance or suicidality received six infusions of ketamine (0.5 mg/kg) during a 12-day period. Depression symptoms were assessed using the Montgomery-Asberg Depression Rating Scale at baseline, day 13 and day 26. Cognitive domains, including processing speed, working memory, visual learning and verbal learning were also measured using the MATRICS Consensus Cognitive Battery at the same time-points. Results: Significant improvement was observed in processing speed at day 13 (effect size [ES] = 0.501) and day 26 (ES = 0.654), and verbal learning at day 13 (ES = 0.362). Path analysis showed significant direct (beta = 2.444, P = 0.017) and indirect (beta = 1.220, P = 0.048) effect of ketamine on processing speed, indicating its improvement was partly independent of improvement in depressive symptoms. The direct effect (beta = 1.963, P = 0.052) of ketamine on verbal learning was not significant, whereas the indirect effect (beta = 1.386, P = 0.024) was significant, indicating treatment with ketamine indirectly improved verbal learning performance, via changes in depressive symptom. Conclusion: Six infusions of ketamine have a potential mood independent pro-cognitive effect on processing speed in adults with treatment depression and/or suicidality. The potential pro-cognitive effects of ketamine provide the basis for hypothesizing that other clinical outcomes (e.g., suicidality, functional impairment) reported with ketamine treatment may be in part mediated by improvement in cognition.
引用
收藏
页码:312 / 319
页数:8
相关论文
共 50 条
  • [1] The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE)
    McIntyre, Roger S.
    Rosenblat, Joshua D.
    Rodrigues, Nelson B.
    Lipsitz, Orly
    Chen-Li, David
    Lee, Jung Goo
    Nasri, Flora
    Subramaniapillai, Mehala
    Kratiuk, Kevin
    Wang, Andrew
    Gill, Hartej
    Mansur, Rodrigo B.
    Ho, Roger
    Lin, Kangguang
    Lee, Yena
    [J]. PSYCHIATRY RESEARCH, 2021, 302
  • [2] Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder
    Covvey, Jordan R.
    Crawford, Alexis Noble
    Lowe, Denise K.
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (01) : 117 - 123
  • [3] Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression
    Shiroma, Paulo R.
    Albott, C. Sophia
    Johns, Brian
    Thuras, Paul
    Wels, Joseph
    Lim, Kelvin O.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 (11): : 1805 - 1813
  • [4] Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
    Price, Rebecca B.
    Nock, Matthew K.
    Charney, Dennis S.
    Mathew, Sanjay J.
    [J]. BIOLOGICAL PSYCHIATRY, 2009, 66 (05) : 522 - 526
  • [5] Intravenous subanesthetic ketamine: an innovative treatment option for rapid response in treatment-resistant depression
    Kang, M.
    Hawken, E.
    Bahji, A.
    Brietzke, E.
    Vazquez, G.
    [J]. EUROPEAN PSYCHIATRY, 2020, 63 : S113 - S113
  • [6] The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine
    McIntyre, Roger S.
    Lipsitz, Orly
    Lui, Leanna M. W.
    Rodrigues, Nelson B.
    Gill, Hartej
    Nasri, Flora
    Ling, Rui
    Teopiz, Kayla M.
    Ho, Roger C.
    Subramaniapillai, Mehala
    Kratiuk, Kevin
    Mansur, Rodrigo B.
    Jones, Brett D. M.
    Lee, Yena
    Rosenblat, Joshua D.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2021, 294 : 592 - 596
  • [7] The bipolar diathesis of treatment-resistant major depressive disorder
    Woo, Young Sup
    Chae, Jeong-Ho
    Jun, Tae-Youn
    Kim, Kwang-Soo
    Bahk, Won-Myong
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2008, 12 (02) : 142 - 146
  • [8] The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence
    McIntyre, Roger S.
    Rodrigues, Nelson B.
    Lipsitz, Orly
    Nasri, Flora
    Gill, Hartej
    Lui, Leanna M. W.
    Subramaniapillai, Mehala
    Kratiuk, Kevin
    Teopiz, Kayla
    Ho, Roger
    Lee, Yena
    Mansur, Rodrigo B.
    Rosenblat, Joshua D.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2021, 35 (02) : 128 - 136
  • [9] Intravenous ketamine therapy in a patient with a treatment-resistant major depression
    Liebrenz, Michael
    Borgeat, Alain
    Leisinger, Ria
    Stohler, Rudolf
    [J]. SWISS MEDICAL WEEKLY, 2007, 137 (15-16) : 234 - 236
  • [10] Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects
    Boydstun, Chelsea
    Lynch, Sean
    DiGenova, Patrick
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2023, 38 (05) : 361 - 366